
DexCom (DXCM) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
DexCom (DXCM) last issued guidance on July 30, 2026 for fiscal year 2026. The company guided revenue in the range of $5.18B - $5.25B for the period.
Compared to prior guidance, DexCom maintained its revenue forecast from a prior range of $5.16B - $5.25B.
DexCom has issued 29 guidance updates between October 27, 2022 and July 30, 2026. During this period, the company raised its outlook 7 times and lowered it 4 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.61 | $0.47 | $0.65 | $0.57 |
| Actual | $0.70 | $0.56 | $0.68 | $0.61 |
| Surprise | +14.8% | +19.1% | +4.62% | +7.02% |
| Revenue | ||||
| Estimate | $1.29B | $1.18B | $1.25B | $1.18B |
| Actual | $1.31B | $1.19B | $1.26B | $1.21B |
| Surprise | +1.25% | +1.29% | +0.61% | +2.54% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.67 | $0.73 | $0.63 | $0.75 |
| Revenue | ||||
| Consensus | $1.33B | $1.40B | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $0.70 | $0.61 | 14.8 % |
| Q1 | Apr 30, 2026 | $0.56 | $0.47 | 19.1 % |
| Q4 | Feb 12, 2026 | $0.68 | $0.65 | 4.62 % |
| Q3 | Oct 30, 2025 | $0.61 | $0.57 | 7.02 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $1.31B | $1.29B | 1.25 % |
| Q1 | Apr 30, 2026 | $1.19B | $1.18B | 1.29 % |
| Q4 | Feb 12, 2026 | $1.26B | $1.25B | 0.61 % |
| Q3 | Oct 30, 2025 | $1.21B | $1.18B | 2.54 % |